
OncoHost is a technology company focused on advancing precision medicine in oncology through its proprietary PROphet® platform. This platform utilizes bioinformatic proteomic pattern recognition and AI to generate a personalized PROphet® score, which predicts patient response to PD-1/PD-L1 inhibitors. The test, performed on plasma or serum samples, provides an all-inclusive evaluation of the tumor and host microenvironment to aid in clinical decision-making and improve patient outcomes. The company is led by an experienced team and supported by a large-scale prospective clinical trial, positioning it as a leader in precision diagnostics and biomarker development.

OncoHost is a technology company focused on advancing precision medicine in oncology through its proprietary PROphet® platform. This platform utilizes bioinformatic proteomic pattern recognition and AI to generate a personalized PROphet® score, which predicts patient response to PD-1/PD-L1 inhibitors. The test, performed on plasma or serum samples, provides an all-inclusive evaluation of the tumor and host microenvironment to aid in clinical decision-making and improve patient outcomes. The company is led by an experienced team and supported by a large-scale prospective clinical trial, positioning it as a leader in precision diagnostics and biomarker development.